IMMpulse study - 1 yr OL, phase 4 trial of risankizumab (150 mg, wk 0, 4) vs apremilast (30 mg bid) in 352 pts w/ moderate plaque psoriasis. RIZ had superior efficacy at wk 16 w/ PASI90 score of 55.9% vs 5.1% for APR. https://t.co/dSLJA9Tsmx https://t.co/AHPHdmOtM3